Trial Profile
A Randomized Phase II Study of Pembrolizumab With or Without Defactinib, a Focal Adhesion Kinase Inhibitor Following Chemotherapy as a Neoadjuvant and Adjuvant Treatment for Resectable Pancreatic Ductal Adenocarcinoma (PDAC)
Status:
Recruiting
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2024
Price :
$35
*
At a glance
- Drugs Defactinib (Primary) ; Pembrolizumab (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Therapeutic Use
- 23 Jan 2024 Planned End Date changed from 1 Jul 2024 to 1 Dec 2024.
- 23 Jan 2024 Planned primary completion date changed from 1 Dec 2023 to 1 Dec 2024.
- 06 Jun 2023 Results assessing quantitative analysis of multiplex immunohistochemistry (mIHC) using 40 biomarkers, evaluating immune and stromal cell types on 14 pre-treatment biopsies and post-treatment resections of PDAC patients, presented at the 59th Annual Meeting of the American Society of Clinical Oncology